These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6121372)

  • 1. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine.
    Järnerot G; Andersen S; Esbjörner E; Sandström B; Brodersen R
    Scand J Gastroenterol; 1981; 16(8):1049-55. PubMed ID: 6121372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation.
    Esbjörner E; Järnerot G; Wranne L
    Acta Paediatr Scand; 1987 Jan; 76(1):137-42. PubMed ID: 2882643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Appearance of sulfasalazine and sulfapyridine in breast milk and in the placental barrier as well as the effect of both substances on bilirubin binding to albumin].
    Järnerot G
    Z Gastroenterol Verh; 1981 Jun; 19():27-8. PubMed ID: 6168129
    [No Abstract]   [Full Text] [Related]  

  • 5. Sulphasalazine treatment during breast feeding.
    Järnerot G; Into-Malmberg MB
    Scand J Gastroenterol; 1979; 14(7):869-71. PubMed ID: 44005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin binding of MADDS--a measure of bilirubin binding--in women during pregnancy and after delivery and in their infants.
    Ebbesen F; Hess J; Brodersen R
    Acta Obstet Gynecol Scand; 1988; 67(5):405-9. PubMed ID: 3218457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].
    Eitner K; Reinicke C; Hippius M
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.
    Azad Khan AK; Truelove SC
    Gut; 1980 Aug; 21(8):706-10. PubMed ID: 6107264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminished bilirubin binding by the serum of pregnant women.
    Ritter DA; Gabai BR; Kenny JD
    Obstet Gynecol; 1985 May; 65(5):633-6. PubMed ID: 3982740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance to therapy in patients on a maintenance dose of sulfasalazine.
    van Hees PA; van Tongeren JH
    J Clin Gastroenterol; 1982 Aug; 4(4):333-6. PubMed ID: 6126499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].
    Guastavino E; Litwin NH; Heffes Nahmod L; Licastro R
    Acta Gastroenterol Latinoam; 1988; 18(2):107-13. PubMed ID: 2908013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reserve albumin and bilirubin toxicity index in infant serum.
    Cashore WJ; Oh W; Brodersen R
    Acta Paediatr Scand; 1983 May; 72(3):415-9. PubMed ID: 6880730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental and mammary transfer of sulphasalazine.
    Khan AK; Truelove SC
    Br Med J; 1979 Dec; 2(6204):1553. PubMed ID: 43760
    [No Abstract]   [Full Text] [Related]  

  • 18. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
    Goldstein PD; Alpers DH; Keating JP
    J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential transplacental binding of diazepam: causes and implications.
    Ridd MJ; Brown KF; Nation RL; Collier CB
    Eur J Clin Pharmacol; 1983; 24(5):595-601. PubMed ID: 6873136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
    Klugmann HJ; Giehler B; Lohmann D; Schiedewitz W
    Gastroenterol J; 1990; 49(4):160-4. PubMed ID: 1970478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.